Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months of low-dose apixaban, experienced…
In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to…
A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid…
The FDA approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [combined positive score ≥…
In a phase III trial (OASIS-4) reported at the 2025 Annual ASCO Meeting and in the New England Journal of Medicine, Cardoso et al attempted…
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared…
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to…
Surgery provides improved long-term survival for patients with pancreatic ductal adenocarcinoma, with a benefit of avoiding metastatic disease but a potential risk for postoperative morbidity…
In a Japanese phase II study (NO LIMIT, WJOG13320G) reported in the Journal of Clinical Oncology, Kawakami et al evaluated whether first-line nivolumab plus low-dose…
Results from the phase III ATOMIC study demonstrated that patients with deficient mismatch repair (dMMR) colon cancer who receive atezolizumab in addition to adjuvant chemotherapy…
Neoadjuvant nivolumab plus chemotherapy significantly improved overall survival rates at 5 years compared with chemotherapy before surgery alone in patients with resectable non–small cell lung…
